North America Pulmonary Drug Delivery Systems Market Outlook

the north american pulmonary drug delivery systems market is expected to reach rapid growth in the upcoming years. this growth is mainly attributed to rising aging population, increasing government initiatives to provide better healthcare services, improving technology and product launches with better features. rising prevalence of several chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease has increased the demand of pulmonary drug delivery systems in this region and it is expected to be a major factor driving the growth of this market in future. nebulizers and inhalers are two key components in pulmonary drug delivery systems market. nebulizers are commonly used for treatment of respiratory diseases, such as asthma, cystic fibrosis, bronchitis, and also to deliver drugs such as antibiotics and pain relief medicines to pediatric patients. inhalers on the other hand includes a steady flow of drugs, which is inhaled directly by a patient. these devices create an aerosol mist for the patient to inhale the medication. inhalers used for delivering medication which is usually in the form of either metered-dose inhalers (mdis) or dry powder inhalers (dpis). major challenges for the market are increasing drug costs, patent expiration for several medications, side effects of the delivery devices, patient compliance efficacy of the drug delivery systems, and high operating costs for the drug delivery systems. key players in this market include teva pharmaceutical industries ltd, glaxosmithkline plc, boehringer ingelheim international gmbh, merck sharp & dohme corp, astrazeneca plc, novartis, amgen inc., and f. hoffmann-la roche ltd. the demand for pulmonary drug delivery systems is increasing due to rise in aging, prevalence of chronic respiratory diseases, and technological advancements. market players are focusing on providing technologically advanced and newly designed products to cater to the needs of consumers. strategic collaborations among market players is witnessed, mainly focused on product launches. therefore, it is expected that north american pulmonary drug delivery systems market will continue to witness substantial growth during the forecast period.